VNP 20009

Drug Profile

VNP 20009

Latest Information Update: 14 Oct 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vion Pharmaceuticals
  • Developer EPTTCO; Vion Pharmaceuticals
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Lymphoma; Solid tumours

Most Recent Events

  • 14 Oct 2002 Discontinued - Phase-I for Cancer in USA (IV-injection)
  • 14 Oct 2002 Discontinued - Phase-I for Lymphoma in England (IV)
  • 14 Oct 2002 Discontinued - Phase-I for Solid tumours in United Kingdom (IV-injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top